Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLIN.L Share News (CLIN)

  • There is currently no data for CLIN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BROKER RATINGS: Upgrades for Old Mutual and Superdry; Drax cut

Thu, 02nd Dec 2021 09:52

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

----------

FTSE 100

----------

DEUTSCHE BANK RAISES NATIONAL GRID PRICE TARGET TO 1,050 (1,020) PENCE - 'BUY'

----------

DEUTSCHE BANK RAISES UNITED UTILITIES PRICE TARGET TO 1,100 (1,050) PENCE - 'HOLD'

----------

DEUTSCHE BANK RAISES SEVERN TRENT PRICE TARGET TO 3,100 (2,900) PENCE - 'BUY'

----------

RBC RAISES NATWEST PRICE TARGET TO 280 (260) PENCE - 'OUTPERFORM'

----------

RBC RAISES LLOYDS PRICE TARGET TO 60 (54) PENCE - 'OUTPERFORM'

----------

RBC RAISES HSBC PRICE TARGET TO 530 (490) PENCE - 'OUTPERFORM'

----------

MORGAN STANLEY RAISES HSBC PRICE TARGET TO 484 (460) PENCE - 'EQUAL-WEIGHT'

----------

RBC RAISES BARCLAYS PRICE TARGET TO 210 (190) PENCE - 'SECTOR PERFORM'

----------

JPMORGAN CUTS BERKELEY GROUP PRICE TARGET TO 5,500 (5,848) PENCE - 'OVERWEIGHT'

----------

GOLDMAN CUTS SCHRODERS PRICE TARGET TO 3110 (3120) PENCE - 'SELL'

----------

FTSE 250

----------

CITIGROUP CUTS DRAX GROUP TO 'NEUTRAL' (BUY) - PRICE TARGET 651 (575) PENCE

----------

BANK OF AMERICA RAISES WORKSPACE GROUP TO 'BUY' (NEUTRAL) - PRICE TARGET 1,010 (1,000) PENCE

----------

JPMORGAN RAISES AUCTION TECHNOLOGY GROUP TARGET TO 1,687 (1,520) P - 'OVERWEIGHT'

----------

DEUTSCHE BANK RAISES PENNON GROUP PRICE TARGET TO 1,260 (1,180) PENCE - 'HOLD'

----------

RBC RAISES PARAGON GROUP PRICE TARGET TO 630 (540) PENCE - 'SECTOR PERFORM'

----------

RBC RAISES OSB GROUP PRICE TARGET TO 700 (650) PENCE - 'OUTPERFORM'

----------

RBC RAISES VIRGIN MONEY PRICE TARGET TO 220 (200) PENCE - 'SECTOR PERFORM'

----------

RBC CUTS CLOSE BROTHERS PRICE TARGET TO 1,450 (1,600) PENCE - 'SECTOR PERFORM'

----------

GOLDMAN SACHS RAISES MAN GROUP PRICE TARGET TO 230 (220) PENCE - 'NEUTRAL'

----------

BERENBERG CUTS EASYJET PRICE TARGET TO 750 (800) PENCE - 'BUY'

----------

JEFFERIES CUTS COUNTRYSIDE PROPERTIES PRICE TARGET TO 606 (642) PENCE - 'BUY'

----------

OTHER MAIN MARKET AND AIM

----------

BANK OF AMERICA RAISES OLD MUTUAL TO 'BUY' (NEUTRAL)

----------

LIBERUM CUTS CLINIGEN PRICE TARGET TO 780 (800) PENCE - 'BUY'

----------

LIBERUM RAISES PENDRAGON PRICE TARGET TO 21 (20) PENCE - 'HOLD'

----------

BERENBERG RAISES IMPAX ASSET MANAGEMENT TARGET TO 1,500 (1,400) PENCE - 'BUY'

----------

RBC CUTS TRIPLE POINT ENERGY EFFICIENCY INFRASTRUCTURE TO 'SECTOR PERFORM' ('OUTPERFORM') TARGET 105 (110) PENCE

----------

RBC RAISES SUPERDRY TO 'OUTPERFORM' (SECTOR PERFORM) - PRICE TARGET 425 (390) PENCE

----------

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
18 Jun 2018 16:22

Abcam Appoints Former Celltech CFO As Non-Executive Chairman

LONDON (Alliance News) - Life sciences company Abcam PLC said Monday it has appointed the former chief financial officer of Celtech Group PLC as a non-executive chairman.Peter Allen is a at

Read more
8 May 2018 12:06

Benchmark Appoints Clinigen Founder And Former Boss As New Chairman

LONDON (Alliance News) - Benchmark Holdings PLC said Tuesday it appointed Peter George as chairman with immediate effect.George founded and was chief executive officer of FTSE-listed Group

Read more
19 Mar 2018 08:34

Clinigen To Run Vyxeos Managed Access Program For Jazz Pharmaceuticals

LONDON (Alliance News) - Pharmaceutical firm Clinigen Group PLC has been appointed by Nasdaq-listed Jazz Pharmaceuticals PLC to distribute Vyxeos via a managed access outside

Read more
25 Jan 2017 16:47

Clinigen profits rise by a third

(ShareCast News) - Global pharmaceutical and services company Clinigen Group provided a trading update for the six months to 31 December on Wednesday, with gross profit up 34%. The AIM-traded firm said this was driven by a combination of "good" organic growth across all divisions, a full six months

Read more
18 Jan 2017 16:07

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
17 Jan 2017 14:10

Clinigen division teams up with TESARO

(ShareCast News) - Clinigen Group announced on Tuesday that its Idis Managed Access division has partnered with TESARO to launch a managed access program for the investigational PARP 1/2 inhibitor, niraparib. The AIM-traded company said Niraparib is being made available for eligible women in the U.S

Read more
9 Jan 2017 15:57

Clinigen enters into second agreement with Cumberland Pharmaceuticals

(ShareCast News) - Clinigen Group, an AIM listed global pharmaceutical and services company, and Cumberland Pharmaceuticals, a US specialty pharmaceutical company have entered into their second exclusive agreement to commercialise the oncology support drug Totect in the US. The first product Clinige

Read more
9 Jan 2017 14:51

Clinigen Group Gives Exclusive US Licence For Totect To Cumberland

Read more
15 Dec 2016 09:08

Clinigen to distribute BioQ's pain relief drug in Europe

(ShareCast News) - AIM-listed pharmaceutical Clinigen is to distribute BioQ Pharma's post-surgery pain management drug, Ropivacaine Readyfusor. The company's subsidiary Idis Global Access has agreed to supply and distribute the pre-filled Ropivacaine Readyfusor for post-operative pain management in

Read more
15 Dec 2016 07:58

Clinigen's Idis Signs Distribution Deal With BioQ Pharma

Read more
1 Dec 2016 11:03

Clinigen and Eisai launch breast cancer treatment in South Africa

(ShareCast News) - Pharmaceutical companies Clinigen and Eisai launched an advanced breast cancer treatment for women in South Africa called Halaven (eribulin). The treatment will benefit around 7,000 women in South Africa that are diagnosed with breast cancer each year. Halaven is now registered b

Read more
1 Dec 2016 07:53

Clinigen's Halaven Breast Cancer Drug Registered In South Africa

Read more
14 Nov 2016 15:07

Director dealings: Clinigen's Bacon slices off a chunk

(ShareCast News) - Clinigen Group director John Bacon has sold £1.4m of the pharmaceuticals and clinical trial services group. Bacon sold 200,000 shares at a price of 717p apiece, but still holds 730,767 shares in the company. He had originally joined the board as a non-executive director last year

Read more
11 Nov 2016 13:40

Clinigen says trading in-line for current FY

(ShareCast News) - Global pharmaceutical and services company Clinigen Group said its trading for the current financial year is in-line with directors' expectations. It said the year to 30 June marked the completion of its transformation into the global market leader in the management and supply of

Read more
11 Nov 2016 07:19

Clinigen Trading In Line With Good Organic, Acquisition-Driven Growth

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.